TABLE 2.
Summary of TEAEs
| All patients receiving cenobamate in the OLE, N = 149, n (%) | |
|---|---|
| Any TEAE | 133 (89.3) |
| TEAE severity | |
| Mild | 42 (28.2) |
| Moderate | 70 (47.0) |
| Severe | 21 (14.1) |
| Serious TEAEs | 38 (25.5) |
| TEAEs in ≥10% of patients | |
| Dizziness | 49 (32.9) |
| Headache | 40 (26.8) |
| Somnolence | 32 (21.5) |
| Viral upper respiratory tract infection | 30 (20.1) |
| Upper respiratory tract infection | 24 (16.1) |
| Nausea | 16 (10.7) |
| Fatigue | 16 (10.7) |
| Urinary tract infection | 16 (10.7) |
Abbreviations: OLE, open‐label extension; TEAE, treatment‐emergent adverse event.